Message from the Guest Editors

Dear Colleagues,

In the last years, new and different biological agents that target specific immunological pathways have been investigated and approved. The establishment of new goals in the management of IBD and the continuation in the understanding of the pathogenetic mechanisms of IBD have allowed the development of new biological drugs and small molecules. We expect promising results and new scenarios through the study of on-going, and future, trials. Thus, with this Special Issue, we are particularly interested in articles that describe the mechanism and the specific targets of these new biological agents and their clinical applications. For detailed information, you can refer to http://www.mdpi.com/journal/ijms/special_issues/IBD_2016.

Prof. Silvio Danese
Prof. Laurent Peyrin-Biroulet
Guest Editors

Author Benefits

Open Access: free for readers, with publishing fees paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed) and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 22 days after submission; acceptance to publication is undertaken in 8 days (median values for 2016).